Amyloid-beta (monoclonal antibody)

Class

Anti-amyloid-beta monoclonal antibody

Amyloid-beta is a small peptide generated by sequential cleavage of a larger transmembrane protein. In some individuals it misfolds and self-associates, progressing from soluble oligomers to protofibrils and finally to the insoluble fibrils that accumulate as extracellular plaques in the brain. This aggregation process is central to the amyloid cascade hypothesis of Alzheimer's disease, which proposes that accumulating amyloid-beta species trigger downstream neuronal injury, inflammation, and eventual cognitive decline. Monoclonal antibodies directed against amyloid-beta are designed to bind specific forms of the peptide—monomers, soluble oligomers, protofibrils, or the fibrillar material within plaques—and to promote their clearance, largely through recruitment of the brain's resident immune cells. Because different antibodies preferentially recognize different conformations, their intended biological effects (soluble species neutralization versus plaque removal) can vary. Active vaccines pursue a related goal by different means: rather than supplying a ready-made antibody, they stimulate a person's own immune system to generate antibodies against amyloid-beta. Across modalities, the shared rationale is that reducing the burden of aggregated amyloid-beta in the brain may slow the neurodegenerative process, making this mechanism a central strategy investigated across the spectrum of Alzheimer's disease and related amyloid-associated conditions.